Novel targets overcome treatment resistance in triple-negative breast cancer

Patients with triple-negative breast cancer (TNBC), an aggressive subtype, currently have limited options and generally face a poor prognosis. Researchers led by Khandan Keyomarsi, Ph.D., Mi Li, Ph.D., and Amriti Lulla, Ph.D., discovered that increased levels of low molecular weight cyclin-E (LMW-E) and cyclin-dependent kinase (CDK1) phosphorylation are associated with poor outcomes following chemotherapy. High levels of LMW-E and CDK1 predicted the poorest treatment responses, suggesting they serve as potential biomarkers of chemotherapy resistance.   The study showed that LMW-E upregulates...

NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained anti-tumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research published today by The University of Texas MD Anderson Cancer Center.   The preclinical findings represent the first evidence that engineering NK cells, a type of innate immune cell, to secrete IL-21 resulted in strong activity against glioblastoma, a cancer type in need of more effective treatment options.   “Our research uncovered a previously unknown...

New small-molecule drug may help people stay strong as they age

New research out of the University of Texas Medical Branch holds promise for helping people maintain strength and mobility as they age.   The research describes how a small-molecule drug being developed at UTMB is superior to intensive resistance/aerobic exercise at improving muscle strength and function in aged mice.   “Amazingly, the strength improvements with our drug were twice those observed with exercise alone,” said Dr. Stanley Watowich, associate professor of Biochemistry & Molecular Biology...

Adding metastasis-directed radiation therapy boosts progression-free survival in metastatic pancreatic cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. Findings from the multicenter EXTEND trial were first presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.   At a median follow-up of 17.3 months, PFS was 10.3 months in patients who received metastasis-directed therapy (MDT) plus chemotherapy compared to only 2.5 months in those who received standard...

UH researchers unveil groundbreaking technique in x-ray imaging

Researchers at the University of Houston unveiled a groundbreaking advancement in X-ray imaging technology that could provide significant improvements in medical diagnostics, materials and industrial imaging, transportation security and other applications.   Mini Das, Moores professor at UH’s College of Natural Sciences and Mathematics and Cullen College of Engineering, and Jingcheng Yuan, a physics graduate student at UH, introduce a novel light transport model for a single-mask phase imaging system that enhances non-destructive deep imaging...

UTMB study shows success with new vaccines to prevent Andes virus

A recent study at the University of Texas Medical Branch has shown that an mRNA vaccine developed by UTMB scientists protects against Andes virus in an animal model. Andes virus is a prominent rodent-borne virus in South America and has human fatality rates up to 30 percent.   “In 2019-2020, Andes virus caused an outbreak in Argentina with 34 confirmed human infections, 11 of which were fatal,” said Dr. Alex Bukreyev, principal investigator on the...

MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.   Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover additional opportunities for ivonescimab, including several tumors outside of its current development plan. MD Anderson will lead multiple clinical trials in several tumor types to...

UTMB researchers develop nasal spray treatment for Alzheimer’s disease

Researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer’s disease and dementia. The study introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.   “This nasal spray approach opens new avenues for non-invasive delivery of tau therapeutic antibodies directly to the brain, and...

Study uncovers new roles for METTL3 in metabolic programming and senescence

A particular area of interest in uncovering the earliest mechanisms driving cancer is a stress response cell state called senescence, in which cells stop growing but continue to function. Senescence has a known role in preventing cancer, but its underlying mechanisms are largely unknown. In a study led by Rugang Zhang, Ph.D., researchers uncovered some of these mechanisms by investigating the role of METTL3, a methyltransferase enzyme that helps regulate gene expression. They found that METTL3...

First-in-human trial yields positive results in prolonging life in young patients with Ewing’s sarcoma

Adolescents and young adults with Ewing’s sarcoma (ES), a highly aggressive bone cancer, have few treatment options and a poor prognosis for recurrence. A multi-center Phase I/II clinical trial co-led by Joseph Ludwig, M.D., investigated the ability of the novel small molecule TK216 to disrupt the oncogenic fusion protein EWS-FLI1 in previously treated, relapsed/recurrent ES. In the study, 85 ES patients between the ages of 11 and 77 received TK216 by a continuous intravenous infusion. Researchers observed...

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives